Skip to main content
MoonLake Immunotherapeutics logo

MoonLake Immunotherapeutics — Investor Relations & Filings

Ticker · MLTX ISIN · KY61559X1045 US Manufacturing
Filings indexed 284 across all filing types
Latest filing 2021-02-16 Major Shareholding Noti…
Country US United States of America
Listing US MLTX

About MoonLake Immunotherapeutics

https://moonlaketx.com/

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company that develops therapies for inflammatory and immunologic diseases by leveraging Nanobody® technology. The company's lead investigational asset is sonelokimab, a Nanobody designed to target key inflammatory pathways. MoonLake is advancing sonelokimab through late-stage clinical development, with Phase 3 programs (VELA and IZAR) underway for the treatment of hidradenitis suppurativa (HS) and psoriatic arthritis (PsA). The company focuses on addressing conditions with significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2021
Major Shareholding Notification
2021-02-16 English
Major Shareholding Notification 2021
Major Shareholding Notification
2021-02-16 English
HELIX ACQUISITION CORP.
Major Shareholding Notification
2021-02-11 English
Major Shareholding Notification 2021
Major Shareholding Notification
2021-02-05 English
QUARTERLY REPORT
Interim / Quarterly Report Q3 2020
2020-12-03 English
HELIX ACQUISITION CORP
Major Shareholding Notification
2020-11-02 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.